Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis
Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis
OBJECTIVES: To assess the efficacy of three different daily doses of acetazolamide in the prevention of acute mountain sickness and to determine the lowest effective dose.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline and Embase along with a hand search of selected bibliographies. No language restrictions were applied.
STUDY SELECTION: Randomised controlled trials assessing the use of acetazolamide at 250 mg, 500 mg, or 750 mg daily versus placebo in adults as a drug intervention for the prophylaxis of acute mountain sickness. Included studies were required to state the administered dose of acetazolamide and to randomise participants before ascent to either acetazolamide or placebo. Two reviewers independently carried out the selection process.
DATA EXTRACTION: Two reviewers extracted data concerning study methods, pharmacological intervention with acetazolamide, method of assessment of acute mountain sickness, and event rates in both control and intervention groups, which were verified and analysed by the review team collaboratively.
DATA SYNTHESIS: 11 studies (with 12 interventions arms) were included in the review. Acetazolamide at doses of 250 mg, 500 mg, and 750 mg were all effective in preventing acute mountain sickness above 3000 m, with a combined odds ratio of 0.36 (95% confidence interval 0.28 to 0.46). At a dose of 250 mg daily the number needed to treat for acetazolamide to prevent acute mountain sickness was 6 (95% confidence interval 5 to 11). Heterogeneity ranged from I(2)=0% (500 mg subgroup) to I(2)=44% (750 mg subgroup).
CONCLUSIONS: Acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are all more effective than placebo for preventing acute mountain sickness. Acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness for which evidence is available.
e6779
Low, Emma V.
de6c052d-0e8f-471a-b4f8-4e8d0cb4490b
Avery, Anthony J.
ba667df1-c7e8-4812-855c-8f5d8c37ed86
Gupta, Vaibhav
f4daf341-1474-4556-9a90-2d66bebc067a
Schedlbauer, Angela
69b5b675-384e-44a2-9474-083f3c9d5e21
Grocott, Michael P.W.
1e87b741-513e-4a22-be13-0f7bb344e8c2
18 October 2012
Low, Emma V.
de6c052d-0e8f-471a-b4f8-4e8d0cb4490b
Avery, Anthony J.
ba667df1-c7e8-4812-855c-8f5d8c37ed86
Gupta, Vaibhav
f4daf341-1474-4556-9a90-2d66bebc067a
Schedlbauer, Angela
69b5b675-384e-44a2-9474-083f3c9d5e21
Grocott, Michael P.W.
1e87b741-513e-4a22-be13-0f7bb344e8c2
Low, Emma V., Avery, Anthony J., Gupta, Vaibhav, Schedlbauer, Angela and Grocott, Michael P.W.
(2012)
Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis.
British Medical Journal, 345, .
(doi:10.1136/bmj.e6779).
(PMID:23081689)
Abstract
OBJECTIVES: To assess the efficacy of three different daily doses of acetazolamide in the prevention of acute mountain sickness and to determine the lowest effective dose.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline and Embase along with a hand search of selected bibliographies. No language restrictions were applied.
STUDY SELECTION: Randomised controlled trials assessing the use of acetazolamide at 250 mg, 500 mg, or 750 mg daily versus placebo in adults as a drug intervention for the prophylaxis of acute mountain sickness. Included studies were required to state the administered dose of acetazolamide and to randomise participants before ascent to either acetazolamide or placebo. Two reviewers independently carried out the selection process.
DATA EXTRACTION: Two reviewers extracted data concerning study methods, pharmacological intervention with acetazolamide, method of assessment of acute mountain sickness, and event rates in both control and intervention groups, which were verified and analysed by the review team collaboratively.
DATA SYNTHESIS: 11 studies (with 12 interventions arms) were included in the review. Acetazolamide at doses of 250 mg, 500 mg, and 750 mg were all effective in preventing acute mountain sickness above 3000 m, with a combined odds ratio of 0.36 (95% confidence interval 0.28 to 0.46). At a dose of 250 mg daily the number needed to treat for acetazolamide to prevent acute mountain sickness was 6 (95% confidence interval 5 to 11). Heterogeneity ranged from I(2)=0% (500 mg subgroup) to I(2)=44% (750 mg subgroup).
CONCLUSIONS: Acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are all more effective than placebo for preventing acute mountain sickness. Acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness for which evidence is available.
This record has no associated files available for download.
More information
Published date: 18 October 2012
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 348854
URI: http://eprints.soton.ac.uk/id/eprint/348854
ISSN: 0959-8138
PURE UUID: 7d45b3ef-d0ca-41f1-9d7c-b632364ca16e
Catalogue record
Date deposited: 20 Feb 2013 15:28
Last modified: 15 Mar 2024 03:33
Export record
Altmetrics
Contributors
Author:
Emma V. Low
Author:
Anthony J. Avery
Author:
Vaibhav Gupta
Author:
Angela Schedlbauer
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics